Rare NRG1 Fusion Market Insights and Treatment Market by DelveInsight

Posted on
by

Rare NRG1 Fusion Market Insights and Treatment Market by DelveInsight

Rare NRG1 Fusion Market report has been added to Delveinsight. It is one of the best comprehensive   and important additions to the market research report.

Rare NRG1 Fusion Disease Overview

NRG1 gene fusions are potentially actionable oncogenic drivers that are present in some solid tumors. NRG1 fusions result in ErbB-mediated pathway activation and present a rational therapeutic target. Solid Tumors are heterotypic aggregates of many cell types, including cancer cells, cancer stem cells, connective-tissue cells, and immune cells. Solid Tumors can develop in the muscles, bone, and organs of the body. Tumor cells have both inherited and somatic variants in their genome. Alterations in oncogenes, tumor-suppressor genes, and micro-RNA genes are important in the pathogenesis of cancer.

Get Free Sample Copy- https://www.delveinsight.com/sample-request/rare-nrg1-fusion-market

Rare NRG1 Fusion Key Players

  • Rain Therapeutics
  • Elevation Oncology
  • Merus
  • AVEO Oncology and CANbridge Pharmaceuticals

Rare NRG1 Fusion Drugs

  • Tarlox (Tarloxotinib Bromide)
  • MM-121 (Seribantumab)
  • Zeno (MCLA-128; Zenocutuzumab)
  • AV-203 (CAN017; ERBB3 MAb)

Rare NRG1 Fusion Market Report

NRG1-fusion proteins and genes in solid tumors are detected primarily using immunohistochemistry and fluorescence in situ hybridization (FISH) techniques, DNA next-generation sequencing (NGS), and targeted gene fusion panels on RNA. The gold standard for the detection of NRG1 gene fusions is RNA sequencing in comparison with DNA sequencing. Genetic sequencing allows the identification of the gene fusion.

Rare NRG1 Fusion Market Insights

For NRG1 fusions, there are currently no approved targeted therapies. Standard therapy for advanced tumors harboring NRG1 fusions remains chemotherapy and/or immunotherapy or novel anti–PD-1 or anti–PD-L1 agents.

Rare NRG1 Fusion Treatment Market

NRG1 gene fusions result in activation of ErbB2-/ErbB3-mediated signaling pathways and may function as oncogenic drivers. NRG1 fusions have emerged as a potential therapeutic target across multiple tumor types, including NSCLC. For NRG1 fusions, there are currently no approved targeted therapies. Standard therapy for advanced tumors harboring NRG1 fusions remains chemotherapy and/or immunotherapy or novel anti–PD-1 or anti–PD-L1 agents.

Rare NRG1 Fusion Market Research Report

The fusions involving the neuregulin-1 gene (NRG1) were first identified by transcriptome sequencing of lung adenocarcinomas, which revealed fusion of CD74 to NRG1. NRG1 fusions are present at a low incidence in multiple tumor types but are enriched in invasive mucinous adenocarcinomas (IMAs) of the lung. NRG1 is an abbreviation for neuregulin-1, sometimes also called heregulin.

Rare NRG1 Fusion Market Report Scope

  • The report covers the descriptive overview of Rare NRG1 Fusion, explaining its causes, signs and symptoms, pathophysiology, and currently available therapies.
  • Comprehensive insight has been provided into the Rare NRG1 Fusion epidemiology and treatment in the 8MM.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Rare NRG1 Fusion is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of the Rare NRG1 Fusion market; historical and forecasted is included in the report, covering drug outreach in the 8MM.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Rare NRG1 Fusion market.

Get Free Sample Copy- https://www.delveinsight.com/sample-request/rare-nrg1-fusion-market

 Table of content

1. Key Insights

2. Report Introduction

3. Rare NRG1 Fusion Market Overview at a Glance

4. Executive Summary of Rare NRG1 Fusion

5. Epidemiology and Market Methodology

6. Disease Background and Overview

7. Epidemiology and Patient Population

8. The United States

9. EU-5

10. Japan

11. China

12. Patient Journey

13. Key Endpoints in NRG1 Fusion Clinical Trials

14. Emerging Therapies

15. Rare NRG1 Fusion: 8 Major Market Analysis

16. The United States Market Size

17. EU-5 Market Size

18. Japan

19. China

20. Market Drivers

21. Market Barriers

22. SWOT Analysis

23. Unmet Needs

24. Appendix

25. DelveInsight Capabilities

26. Disclaimer

27. About DelveInsight

 

Why should you buy this report?

  • The report will help in developing business strategies by understanding trends shaping and driving the Rare NRG1 Fusion market.
  • To understand the future market competition in the Rare NRG1 Fusion market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Rare NRG1 Fusion in the US, Europe (Germany, France, Italy, Spain, and the United Kingdom) Japan, and China.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the Rare NRG1 Fusion market.
  • To understand the future market competition in the Rare NRG1 Fusion market.

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/